Mitochondrial dysfunction drives age-related degeneration of the thoracic aorta.
Mitochondrial dysfunction appears to drive aortic aging, and targeting it with peptides like elamipretide may have potential for future research.
Where it sits
this study against the rest of the ss-31 corpusSummary and findings
This study measured the impact of the mitochondrial-targeted peptide elamipretide (SS-31) on aortic aging in C57Bl/6 J mice. Young (5-6 month) and aged (24-25 month) mice received ELAM for 8 weeks. The treatment restored complex II-linked respiration and reduced inflammatory markers in aged mice.
Abstract
This study investigated the role of mitochondrial function in aortic aging. As the aorta ages, it becomes stiffer and less compliant, increasing the risk of aneurysmal disease, hypertension, and diastolic dysfunction. Given the role of mitochondrial dysfunction in non-age related aortopathies and as a hallmark of aging, we investigated its contribution to the aging aorta. Both male and female young (5-6 month) and aged (24-25 month) C57Bl/6 J mice received mitochondrial-targeted peptide elamipretide (ELAM; SS-31) for 8 weeks. ELAM restored complex II-linked respiration in aged mice to values seen in young mice, while also improving relative phosphorylative flux. ELAM treatment also reduced inflammatory MMP9 expression and elastin breaks in aged mice. Bulk RNAseq analysis revealed that ELAM treatment significantly affected the aortic transcriptome in an age-dependent manner, reducing the expression of senescent and associated pro-inflammatory genes. Mitochondrial dysfunction thus drives aortic aging and is a potential therapeutic target for future study.
Background
Not reported in abstract.
Methods
Not reported in abstract.
Results
Not reported in abstract.
Interpretation
Not reported in abstract.
Limitations
Not reported in abstract.